三生国健：2025年净利同比预增311% 收到辉瑞就707项目支付的首付款确认收入约28.90亿元

Core Viewpoint - Sanofi Guojian (688336.SH) forecasts a significant increase in net profit for 2025, projecting approximately 2.9 billion yuan, representing a year-on-year growth of 311.35% [1] Financial Performance - The company expects substantial growth in operating revenue and net profit attributable to shareholders due to a key collaboration with Pfizer Inc. [1] - The revenue recognized from Pfizer for the 707 project is approximately 2.89 billion yuan, contributing to the anticipated increase in financial metrics for 2025 [1]